Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?
暂无分享,去创建一个
[1] L. Hann,et al. Advances in the detection of residual thyroid carcinoma. , 2001, Advances in internal medicine.
[2] S. Larson,et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[3] M. New. PRENATAL TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA: The United States Experience , 2001 .
[4] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[5] Y. Menda,et al. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] B. van Eck-Smit,et al. Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. , 1993, Nuclear medicine communications.
[7] E. Baudin,et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.
[8] R. Simó,et al. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors]. , 1997, Medicina clinica.
[9] R. Harvey,et al. Measurement of serum thyroglobulin is of value in detecting tumour recurrence following treatment of differentiated thyroid carcinoma by lobectomy , 1990, The British journal of surgery.
[10] R. Kloos,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .
[11] H. Burch,et al. Serum thyroglobulin measurement. Utility in clinical practice. , 2001 .
[12] Steven J Brown,et al. The role of iodine‐131 and thallium‐201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma , 1993, Cancer.
[13] A. Pinchera,et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[14] E. Bergstralh,et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? , 1998, Surgery.
[15] H. Gharib,et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[16] S. Larson,et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.
[17] B. Weintraub,et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.
[18] O. Clark,et al. Prognostic factors in thyroid carcinoma. , 1997, Surgical oncology clinics of North America.
[19] A. Avraham,et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] G. Ronga,et al. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma. , 1986, The Italian journal of surgical sciences.
[21] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[22] P. Mikosch,et al. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] M. Schlumberger,et al. Papillary and follicular thyroid carcinoma. , 1998, The New England journal of medicine.
[24] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.
[25] P. Ladenson,et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. , 1996, Archives of internal medicine.